Post by jckrdu on Feb 25, 2020 13:45:35 GMT
www.esperion.com/
I like this company as a long-term holding. Cholesterol lowering drug just approved by FDA earlier this week. Second drug likely to be approved by FDA on 2/26/2020 PDUFA date. Europe approvals likely coming in April, as EU CHMP Committee gave a positive opinion. Commercial ramp in process in US. Anyone interested should listen to recent CEO presentation at JPM conference, as well as recent press releases. IMO, undervalued anywhere in $60s or $70s.
Future PPS direction likely driven from prescriptions written and market uptake. Products are good and fill a real need, so I'm bullish long-term.
Some key upcoming milestones below:
2/26 - FDA approval of combo drug.
April - EU Approvals of 2 drugs.
April - ROW (Rest of World) Partnership
2nd QTR / Early 3rd QTR - Second $150M milestone payment from Daichi as part of EU partnership (Triggered by 1st drug sale in EU).
Some key risks (from my perspective): (These risks are also potential catalysts if they are addressed.)
Late Feb / Early March - During earnings call, they'll likely layout their projected operating expenses for the next 12 months. Market may not like increased burn.
April - Prescriptions written will be transparently reported by the company starting 4/10 on a public database. Prescriptions written may not meet market expectations.
I like this company as a long-term holding. Cholesterol lowering drug just approved by FDA earlier this week. Second drug likely to be approved by FDA on 2/26/2020 PDUFA date. Europe approvals likely coming in April, as EU CHMP Committee gave a positive opinion. Commercial ramp in process in US. Anyone interested should listen to recent CEO presentation at JPM conference, as well as recent press releases. IMO, undervalued anywhere in $60s or $70s.
Future PPS direction likely driven from prescriptions written and market uptake. Products are good and fill a real need, so I'm bullish long-term.
Some key upcoming milestones below:
2/26 - FDA approval of combo drug.
April - EU Approvals of 2 drugs.
April - ROW (Rest of World) Partnership
2nd QTR / Early 3rd QTR - Second $150M milestone payment from Daichi as part of EU partnership (Triggered by 1st drug sale in EU).
Some key risks (from my perspective): (These risks are also potential catalysts if they are addressed.)
Late Feb / Early March - During earnings call, they'll likely layout their projected operating expenses for the next 12 months. Market may not like increased burn.
April - Prescriptions written will be transparently reported by the company starting 4/10 on a public database. Prescriptions written may not meet market expectations.
